BXRXQ — Baudax Bio Cashflow Statement
0.000.00%
Last trade - 00:00- $0.29m
- $14.20m
- $1.27m
Annual cashflow statement for Baudax Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -73.7 | -32.6 | -76.1 | -19.8 | -58.8 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 13.1 | -9.09 | 28.9 | -29.2 | 28.8 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.447 | -8.88 | 0.633 | -3.08 | 0.062 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -59.8 | -50 | -44.1 | -49.3 | -27.8 |
| Capital Expenditures | -3.45 | -1.48 | -0.639 | -0.203 | -0.02 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | — | 0.009 | 0 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -3.45 | -1.48 | -0.639 | -0.194 | -0.02 |
| Financing Cash Flow Items | 63.2 | 69.3 | 17.9 | 22.9 | 0.354 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 63.2 | 69.3 | 57.3 | 35 | 17.2 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0 | 17.7 | 12.6 | -14.5 | -10.6 |